We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Walgreens Boots (WBA) Stock Looks Like A Cheap, Solid Buy Right Now
Read MoreHide Full Article
Shares of Walgreens Boots Alliance (WBA - Free Report) jumped roughly 1.6% Monday as investors continue to dive in after it posted impressive fiscal fourth-quarter results late last week. Looking ahead, the pharmaceutical giant looks poised for strong growth and WBA stock seems like it might be worth buying right now.
Q4 Overview
Walgreens saw its adjusted fiscal fourth-quarter earnings jump 13% to hit $1.48 per share, which topped the Zacks Consensus Estimate of $1.44. The drugstore powerhouse’s Q4 revenues climbed nearly 11% to reach $33.44 billion.
Walgreens’ prescription business stood out in Q4, bolstered by its $4.4 billion purchase of roughly 1,900 Rite Aid pharmacies earlier this year. Investors should also note that the Deerfield, Illinois-based company’s share of the U.S. retail prescription market jumped from 20.2% in fiscal 2017 to 21.7%, based on data from health-care research firm Iqvia. This marked the company’s highest ever annual share, while its market share hit 22.3% in Q4.
The firm said that it filled the largest number of prescriptions in its 117-year history, which helped its U.S. pharmacy sales surge 17%.
Forward-Looking Push
Now that we have quickly covered some of Walgreens’ fiscal Q4 highlights it’s time to look at some of the firm’s recent moves that help set it up to better compete not only against CVS (CVS - Free Report) and Target (TGT - Free Report) but also Amazon (AMZN - Free Report) and other giants.
Walgreens recently partnered with and took a minority stake in the subscription-based beauty firm Birchbox in order to offer more high-end cosmetics and attract more millennial customers. The firm also launched a pilot program with Kroger (KR - Free Report) that will see it test out selling grocery offerings at Walgreens.
The company in late September launched a Boots flagship store on Alibaba’s (BABA - Free Report) Tmall platform. Plus, Walgreens purchased a 40% stake in a leading Chinese retail pharmacy chain, Sinopharm Holding GuoDa Drugstores Co. earlier this year.
Investors should also note that Walgreens offers a range of delivery and shipping options and is likely to expand these efforts going forward.
Valuation
We can see that WBA stock has performed alright over the last 12 months. And he company's stock is up roughly 34% over the last five years. However, shares of Walgreens have slipped over 14% during the last 36 months. With that said, WBA’s valuation picture looks impressive at the moment.
Walgreens stock is currently trading at 11.2X forward 12-month Zacks Consensus EPS estimates, which marks a substantial discount compared to its industry’s 17.2X average. Plus, WBA has traded as high as 13.5X during the past year and 23.3X over the last five years. We can also see that Walgreens is trading near its five-year lows, which means WBA appears rather “cheap” at the moment.
Outlook
Looking ahead, Walgreens’ Q1 revenues are projected to climb by 11.1% to hit $34.16 billion, based on our current Zacks Consensus Estimate. Meanwhile, Walgreens is expected to see its adjusted quarterly earnings pop by 12.5% to reach $1.44 per share.
Bottom Line
It is also worth noting that Walgreens has earned eight positive earnings estimate revisions for its current fiscal year and the following year over the last seven days, with 100% agreement to the upside. This helps Walgreens earn a Zacks Rank #2 (Buy) at the moment. The company also rocks an “A” grade for Growth and a “B” for Value in our Style Scores system.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Walgreens Boots (WBA) Stock Looks Like A Cheap, Solid Buy Right Now
Shares of Walgreens Boots Alliance (WBA - Free Report) jumped roughly 1.6% Monday as investors continue to dive in after it posted impressive fiscal fourth-quarter results late last week. Looking ahead, the pharmaceutical giant looks poised for strong growth and WBA stock seems like it might be worth buying right now.
Q4 Overview
Walgreens saw its adjusted fiscal fourth-quarter earnings jump 13% to hit $1.48 per share, which topped the Zacks Consensus Estimate of $1.44. The drugstore powerhouse’s Q4 revenues climbed nearly 11% to reach $33.44 billion.
Walgreens’ prescription business stood out in Q4, bolstered by its $4.4 billion purchase of roughly 1,900 Rite Aid pharmacies earlier this year. Investors should also note that the Deerfield, Illinois-based company’s share of the U.S. retail prescription market jumped from 20.2% in fiscal 2017 to 21.7%, based on data from health-care research firm Iqvia. This marked the company’s highest ever annual share, while its market share hit 22.3% in Q4.
The firm said that it filled the largest number of prescriptions in its 117-year history, which helped its U.S. pharmacy sales surge 17%.
Forward-Looking Push
Now that we have quickly covered some of Walgreens’ fiscal Q4 highlights it’s time to look at some of the firm’s recent moves that help set it up to better compete not only against CVS (CVS - Free Report) and Target (TGT - Free Report) but also Amazon (AMZN - Free Report) and other giants.
Walgreens recently partnered with and took a minority stake in the subscription-based beauty firm Birchbox in order to offer more high-end cosmetics and attract more millennial customers. The firm also launched a pilot program with Kroger (KR - Free Report) that will see it test out selling grocery offerings at Walgreens.
The company in late September launched a Boots flagship store on Alibaba’s (BABA - Free Report) Tmall platform. Plus, Walgreens purchased a 40% stake in a leading Chinese retail pharmacy chain, Sinopharm Holding GuoDa Drugstores Co. earlier this year.
Investors should also note that Walgreens offers a range of delivery and shipping options and is likely to expand these efforts going forward.
Valuation
We can see that WBA stock has performed alright over the last 12 months. And he company's stock is up roughly 34% over the last five years. However, shares of Walgreens have slipped over 14% during the last 36 months. With that said, WBA’s valuation picture looks impressive at the moment.
Walgreens stock is currently trading at 11.2X forward 12-month Zacks Consensus EPS estimates, which marks a substantial discount compared to its industry’s 17.2X average. Plus, WBA has traded as high as 13.5X during the past year and 23.3X over the last five years. We can also see that Walgreens is trading near its five-year lows, which means WBA appears rather “cheap” at the moment.
Outlook
Looking ahead, Walgreens’ Q1 revenues are projected to climb by 11.1% to hit $34.16 billion, based on our current Zacks Consensus Estimate. Meanwhile, Walgreens is expected to see its adjusted quarterly earnings pop by 12.5% to reach $1.44 per share.
Bottom Line
It is also worth noting that Walgreens has earned eight positive earnings estimate revisions for its current fiscal year and the following year over the last seven days, with 100% agreement to the upside. This helps Walgreens earn a Zacks Rank #2 (Buy) at the moment. The company also rocks an “A” grade for Growth and a “B” for Value in our Style Scores system.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>